October 17th, 2024 – Solvotrin Therapeutics, a leading Irish healthcare development company, is delighted to announce the signing of a long-term licensing agreement with Norwell Consumer Healthcare for the Active Iron brand in Canada. Norwell Consumer Healthcare, an affiliate of Pharmascience, one of Canada’s largest pharmaceutical manufacturers, is known for providing trusted over-the-counter (OTC) solutions to meet the health and wellness needs of Canadians.

The partnership marks an exciting expansion for Active Iron, a clinically proven iron supplement, into the Canadian market. Active Iron will be integrated into Norwell’s Women’s Health portfolio under Weliva™ a brand that supports women through various life stages by offering convenient solutions to relieve symptoms related to hormonal changes and associated conditions.

“We’re incredibly excited to launch Active Iron in Canada in 2025,” said Ronan McClafferty, Chief Operating Officer at Solvotrin. “This partnership is built on a shared vision of improving health outcomes, and we are confident that Norwell’s strong presence and expertise in Canada will help us make a meaningful impact on women’s health.”

David Bloom, General Manager of Norwell Consumer Healthcare, expressed his enthusiasm for the collaboration: “We are thrilled to partner with Solvotrin Therapeutics to bring Active Iron to the Canadian market. At Norwell, we are always looking for clinically proven, innovative products that align with our mission of helping Canadians address their health and wellness needs. Active Iron is an innovative addition to our Weliva™ brand, and we believe it will be a game-changer for women seeking an effective iron supplement.”

Weliva™ is dedicated to helping women navigate different phases of their lives, offering products that empower them to thrive. The brand provides easy and convenient solutions for addressing concerns related to hormonal shifts in different life stages, making Active Iron an ideal fit for the brand.

Since its inception, Norwell Consumer Healthcare has established a strong reputation as a trusted partner in Canada, with a focus on providing over-the-counter solutions backed by scientific evidence. This new collaboration with Solvotrin further strengthens their portfolio and underscores their commitment to offering high-quality products that meet the evolving needs of Canadians.

About Solvotrin:

Solvotrin Therapeutics is an Irish healthcare development company focused on optimising established therapies through innovation with patent protection. Solvotrin has developed and successfully commercialised the Active Iron platform technology, led by a range of innovative oral iron products branded as Active Iron. Active Iron is now available in 15 markets worldwide.

About Norwell Consumer Healthcare:

Norwell Consumer Healthcare Inc. is a stand-alone consumer health care company that has the agility and flexibility to lead growth within the OTC category. Norwell Consumer Healthcare’s vision is to help Canadians manage their health and wellbeing by offering trusted, clinically proven OTC solutions to meet their under-served health and wellness needs. Norwell’s brand portfolio includes brands such as Weliva®, Lax-A-Day®, Hemovel®, Cystoplus®, Helixia®, and Rhinaris®.

About Pharmascience:

Founded in 1983, Pharmascience Inc. is the largest Canadian-owned pharmaceutical company with 1,600 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries.

Norwell Press Release